Picture of Abeona Therapeutics logo

ABEO — Abeona Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapSucker Stock

Abeona Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

* Abeona Therapeutics Inc  ABEO.OQ   ABEO.O  is expected
to show a
rise in quarterly revenue when it reports  results on November
11 (estimated) for the period ending September 30 2024
    * The Cleveland Ohio-based  company is expected to report
revenue
of $100 thousand, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Abeona Therapeutics Inc
is for
a loss of 40 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Abeona
Therapeutics Inc is 16.50​, above​ its last closing price
of $6.38. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.39       -0.36      0.19      Beat    152.2
 Jan. 1 2024   -0.51       -0.51      -1.16     Missed  -126
 Dec. 31 2023              -0.47      -0.77     Missed  -63.8​
 Sep. 30 2023  -0.53       -0.53      -0.48     Beat    8.9
 ​​Jun.        -0.71       -0.68      -0.92     Missed  -35.3
 30 2023                                                
 Mar. 31 2023  -0.62       -0.58      -0.54     Beat    6.9​
 Dec. 31 2022              -0.75      1.53      Beat    304
 Jan. 1 0001   -1.75       -1.75      -1.48     Beat    15.3
 This summary was machine generated November 8 at 15:38 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Abeona Therapeutics

See all news